Drug Discovery

Harbour BioMed, Moderna partner on immunotherapies development

Harbour BioMed’s wholly owned subsidiary Nona Biosciences and global biotechnology firm ModernaTX have entered into a license and collaboration deal for the development of immunotherapies.

Navrogen signs agreement with US NCI for NAV-001 development

Navrogen has signed a cooperative research and development agreement (CRADA) with the US National Cancer Institute (NCI) researchers for the clinical development of NAV-001.

Amgen’s olpasiran reduces cardiovascular disease risk factor in Phase II study

Amgen has reported positive end-of-treatment data from the Phase II OCEAN(a)-DOSE study of its investigational olpasiran (formerly AMG 890).

PharmaTher, CWRU enter into agreement for Rett Syndrome therapy development

PharmaTher and Case Western Reserve University (CWRU) have entered into an evaluation and exclusive option agreement for the development and commercialisation of ketamine to treat Rett Syndrome.

EpiVax partners with Intravacc, CEPI for betacoronavirus vaccine development

EpiVax is joining Intravacc and Coalition for Epidemic Preparedness Innovations (CEPI) on a new project to develop universal vaccines for betacoronaviruses, including SARS-CoV-2.

Ariceum, AmbioPharm partner to produce and supply peptide conjugates

Private biotech firm Ariceum Therapeutics has entered into a strategic partnership deal with AmbioPharm to produce and supply peptide conjugates.

Normunity raises funds to develop immuno-oncology therapies

Biotechnology company Normunity has raised $65m in Series A financing round for expanding the frontier of precision immuno-oncology with immune normaliser therapies.

FDA grants priority review for Daiichi Sankyo’s AML medicine

The US Food and Drug Administration (FDA) has granted priority review for Daiichi Sankyo’s quizartinib along with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy to treat newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML).

Jazz and Zymeworks sign license agreement for antibody development

Jazz Pharmaceuticals has entered into an exclusive licensing agreement with Zymeworks' subsidiary, Zymeworks BC to develop and commercialise the latter’s HER2-targeted bispecific antibody, Zanidatamab.